Viatris launches $36.50 per share tender offer to acquire Pacira BioSciences

Viatris Inc. has initiated a tender offer to buy all outstanding shares of Pacira BioSciences at $36.50 per share in cash. This move follows a merger agreement where Viatris' subsidiary will merge into Pacira, making it a wholly owned subsidiary. The offer, recommended unanimously by Pacira's board, expires on Nov. 16, 2026, and requires at least 50% of shares tendered to proceed. The acquisition aims to expand Viatris' healthcare portfolio and is subject to regulatory approvals and other conditions.

As of Oct 30, 2026 19:51 WIB, Viatris Inc. (VTRS) is trading at USD 19.38 on Pluang, showing a 1-day gain of 0.94%. The company's market capitalization stands at $22.08 billion, reflecting steady investor interest. This trading activity occurs while Viatris pursues its tender offer to acquire Pacira BioSciences, highlighting ongoing strategic moves in the healthcare sector.